Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › velcade

velcade

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of velcade

11 trials tracked of velcade: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 151 citations.

11Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 8 Other / NA 1
  1. Phase 3 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Completed · 151 cited
  2. Phase 4 Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Completed
  3. Phase 2 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma Completed
  4. Phase 2 Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  5. Phase 2 UARK 2003-33, Total Therapy III Completed
  6. Phase 2 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis Completed
Show 5 more trials
  1. Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed
  2. Phase 2 A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma Completed
  3. Phase 2 Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma Completed
  4. Phase 2 First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Completed
  5. N/A UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma
Allergy & Immunology Meta-analysis
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma New data ranks best treatments for transplant-ineligible multiple myeloma
This network meta-analysis of 6 trials involving 3162 patients evaluated various treatment nodes for transplant-ineligible newly diagnosed m…
A large review of 3,162 patients reveals which combinations of drugs work best to keep multiple myeloma from progressing.
Frontiers Aug 24, 2026